SCHEMBL7642433

SCHEMBL7642433

CCn1c2ccccc2c2cc(N(C)C)ccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.61
KDM4E B2RXH2 6/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
HTT P42858 2/20 0.61
ALDH1A1 P00352 2/20 0.61
MAPK1 P28482 2/20 0.61
HPGD P15428 1/20 0.61
HBB P68871 1/20 0.61
HSD17B10 Q99714 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
NPY5R Q15761 2/20 0.54
LMNA P02545 5/20 0.54
DRD3 P35462 1/20 0.53
POLB P06746 2/20 0.52
PKM P14618 1/20 0.52
RORC P51449 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
SRC P12931 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17298315 0.91 KDM4E (0.47) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL9764919 0.87 KDM4E (0.58) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL279090 0.86 MAPT (0.56) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL12559388 0.85 MAPT (0.59) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL11578537 0.85 MAPT (0.59) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL4635069 0.85 KDM4E (0.54) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL4635172 0.84 MAPT (0.51) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL14465443 0.83 MAPT (0.55) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL12856894 0.83 KDM4E (0.44) MAPTKDM4EMEN1KMT2AHTT
SCHEMBL24359531 0.83 MAPT (0.56) MAPTKDM4EMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020102246-A1 Antimicrobial compositions NOVOZYMES A/S (DK) 2002-08-01 US claimed
WO-2001084937-A1 OXIDOREDUCTASE MEDIATED ANTIMICROBIAL ACTIVITY NOVOZYMES A/S (DK) 2001-11-15 WO claimed
US-20020102246-A1 Antimicrobial compositions NOVOZYMES A/S (DK) 2002-08-01 US disclosed
WO-2001084937-A1 OXIDOREDUCTASE MEDIATED ANTIMICROBIAL ACTIVITY NOVOZYMES A/S (DK) 2001-11-15 WO disclosed
US-4465761-A HALO COMPOUND, LEUCO DYE, AROMATIC AMINE SENSITIZER, BINDER AND ALIPHATIC AMINE; ANTIFOGGING AGENTS ORIENTAL PHOTO INDUSTRIES CO., LTD. (JP) 1984-08-14 US disclosed
EP-0026859-B1 IMAGE-FORMING PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE COATING SOLUTION AND PHOTOSENSITIVE SHEET COMPRISING THIS COMPOSITION ORIENTAL PHOTO INDUSTRIES, CO., LTD. (JP) 1983-10-05 EP disclosed
EP-0026859-A2 Image-forming photosensitive composition, photosensitive coating solution and photosensitive sheet comprising this composition ORIENTAL PHOTO INDUSTRIES, CO., LTD. (JP) 1981-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102246-A1 Antimicrobial compositions LCT, LPO, MPO MAPT 2626/4885KDM4E 3089/4885MEN1 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.